Chalk River, Ontario, January 16, 2025 – Actineer, a joint venture between ITM and Canadian Nuclear Laboratories (CNL) Ltd., today announced the appointment of Joseph Oliverio as President and Chief Executive Officer. With extensive industry leadership experience, Mr. Oliverio is poised to drive Actineer’s global expansion in Actinium-225 (Ac-225) production.
Mr. Oliverio joins Actineer with over three decades of leadership experience across the nuclear medicine, medical device and radiopharmaceutical industries, including at Ionetix, IMAGIN Molecular Corporation and Positron Corporation (OTC: POSC). He takes the helm as Actineer moves forward with the scaling of its Ac-225 manufacturing capabilities and preparations to supply the radiopharmaceutical industry with this valuable alpha emitter.
“Actinium-225 holds promising potential in cancer treatment. With the appointment of Joseph Oliverio as President and CEO of Actineer, the Joint Venture is well-positioned to shape the future of this critical field,” said Dr. Andrew Cavey, CEO of ITM and Actineer Board Chairman. “His expertise will be instrumental in advancing the team’s efforts to ensure a reliable and scalable supply of Actinium-225, in an effort to meet the global demand."
“With the appointment of Joseph as President and CEO, we are embarking on a new phase in Actineer’s corporate development,” said Jack Craig Jr., President and CEO of CNL and Actineer Board Member. “Joseph’s leadership experience across radiopharmaceutical organizations, particularly in driving growth strategies for alpha therapy segments and overseeing joint ventures, will be an invaluable asset as we ramp up our production efforts for GMP-grade Actinium-225 and begin supplying Actineer’s partners.”